<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01511419</url>
  </required_header>
  <id_info>
    <org_study_id>LAIV-H7N3-01</org_study_id>
    <nct_id>NCT01511419</nct_id>
  </id_info>
  <brief_title>Safety Trial of Live Attenuated Influenza (H7N3) Vaccine</brief_title>
  <official_title>Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Mallard/Netherlands/00/95 (H7N3) Influenza Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Russian Federation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Research Institute of Influenza, Russia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Experimental Medicine, Russia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PATH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is that two doses of cold-adapted, live monovalent
      A/17/mallard/Netherlands/00/95 (H7N3) influenza vaccine will be safe and immunogenic in
      healthy adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I, double-blind, individually-randomized (3:1, vaccine:placebo), controlled
      trial with two groups, LAIV H7N3 and matched placebo. Healthy male and female adults 18
      through 49 years of age will be invited to participate. For feasibility reasons and in order
      for an independent Safety Monitoring Committee (SMC) to review safety data in a small group
      of subjects initially, the total cohort of 40 subjects will be enrolled in two sub-cohorts:
      one cohort of 12 subjects, randomized at 3:1 (9 vaccine and 3 placebo), followed two weeks
      later by a second cohort of 28 subjects randomized at 3:1 (21 vaccine and 7 placebo). After
      all 12 volunteers of the first sub-cohort have been observed for the first isolation period
      (Day 1 to Day 7), an interim safety review will be performed by the SMC. The SMC will review
      all adverse events (AEs), including clinical laboratory evaluations (pre- and
      post-vaccination) and shedding data, for all subjects and will advise if the volunteers of
      the first sub-cohort may receive dose two of study vaccine or placebo and if the additional
      28 volunteers of the second sub-cohort may be enrolled into the study. As for the first
      sub-cohort, the SMC will also review all safety data for the second sub-cohort and for the
      entire participant population of the trial. For each sub-cohort, the procedures and timelines
      are here summarized.

      On the day of first screening, about 7 days (between 4 and 14 days) prior to administration
      of dose one of study vaccine or placebo, subjects will be screened for eligibility through
      medical history review, physical examination, testing for serologic evidence of chronic viral
      infection [human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus
      (HCV), with proper pre- and post-test counseling], routine biochemical and hematological
      blood tests and urinalysis by dipstick.

      Subject screening for eligibility will continue and be completed on the second screening day
      (S2). This second screening day will occur the same day as scheduled admission to the
      isolation unit and administration of study vaccine or placebo (Day 0). Women will undergo
      pregnancy tests using urine samples. All subjects will undergo an ear, nose and throat (ENT)
      examination. Fully eligible subjects will be admitted to the isolation unit. At that time,
      nasal swab, nasal wick, and blood specimens will be collected for virologic and immunological
      testing prior to administration of study vaccine or placebo. Blood and urine specimens will
      be again collected for routine biochemical and hematological blood tests and urinalysis by
      dipstick; these results will serve to define baseline status for subject prior to receipt of
      study vaccine or placebo but will not be used for screening purposes. Subjects will be
      unaware of which allocation, LAIV H7N3 or matched placebo, is received; study vaccine and
      placebo will be masked. Subjects will be carefully monitored for adverse reactions while in
      the isolation unit.

      All subjects will remain in the isolation unit for at least 7 days after receipt of study
      vaccine or placebo. Nasal swabs will be collected daily while subjects are in isolation to
      test for presence of influenza virus shed in the nasal passage. Any subject exhibiting
      conjunctivitis will also have a conjunctival swab collected on the day of appearance of the
      sign. Any subject exhibiting influenza A virus shedding, as determined by real-time reverse
      transcriptase polymerase chain reaction (RT-PCR) positivity on a nasal swab specimen, in the
      2 days prior to each planned discharge day after each dose (Days 6 or 7 or Days 34 or 35)
      will be kept in the isolation until PCR-diagnosis results confirm that no influenza virus is
      present in a tested clinical specimen for at least two consecutive days. Any subject still
      exhibiting evidence of influenza virus shedding in a nasal swab on Days 6 or 7 or Days 34 or
      35 post-administration with each dose might be placed on influenza antiviral (oseltamivir)
      treatment at the standard dose for treatment of 75 milligrams (mg) twice a day for a course
      of 5 days.

      After discharge from the isolation unit, subjects will complete diary cards for AEs and use
      of concomitant medications. Subjects will return to the isolation unit at four weeks (Day 28)
      after administration of dose one of study vaccine or placebo. At that time, similar
      procedures will be used for admittance to the isolation unit, for receipt of dose two of
      study vaccine or placebo and for isolation and follow-up, with the additional procedure of
      review of interim histories (and diary cards) since first discharge after dose one.

      After second discharge from the isolation unit, subjects will again complete diary cards for
      AEs and use of concomitant medications. Subjects will then return to the study center at four
      weeks (Day 56) after administration of dose two of study vaccine or placebo for their final
      study visit. Interim histories (and diary cards) will again be reviewed and final blood and
      nasal wick specimens will be collected. Women will also undergo a final pregnancy screen.
      Subjects will complete the study at this time.

      For assessment of safety, subjects will be observed for two hours after each administration
      of study vaccine or placebo. Twice daily (early morning and late afternoon) examination will
      be also used to assess reactions for 7 days after each administration of study vaccine or
      placebo. ENT examination will also occur once per day on Days 7, 28, 35 and 56. Subjects will
      complete diary cards for unsolicited AEs from the day of each discharge until return to the
      isolation unit for dose two (at Day 28) or until return to the study center for the final
      study visit at four weeks post dose two (at Day 56). To assess safety, blood and urine
      specimens will also be collected on days 7, 28 (prior to administration of dose two of study
      vaccine or placebo), 35 and 56, for testing by routine biochemical and hematological blood
      tests and by urinalysis by dipstick.

      For the evaluation of mucosal immunoglobulin A (IgA) antibody, nasal wick specimens will be
      collected on Day 0 (prior to administration of dose one of study vaccine or placebo), on Day
      28 (prior to administration of dose two of study vaccine or placebo) and on Day 56. For the
      evaluation of serum antibodies (by hemagglutination inhibition [HAI], microneutralization and
      IgA and immunoglobulin G [IgG] EIA), serum specimens will be collected on Day 0 (prior to
      administration of dose one of study vaccine or placebo), on Day 28 (prior to administration
      of dose two of study vaccine or placebo) and on Day 56. To study virus infectivity (by
      isolation in chicken embryos) and stability (by molecular sequencing of any isolated virus),
      nasal swab specimens will be taken on Days 1, 2, 3, 5, 7, 29, and 31. To assess priming and
      stimulation of cytotoxic T lymphocytes and other cytokine indicators, whole blood for
      isolation of peripheral blood mononuclear cells (PBMCs) will be collected on Days 0 (prior to
      administration of dose one of study vaccine or placebo), on Day 28 (prior to administration
      of dose two of study vaccine or placebo) and on Day 56.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Immediate Reactions</measure>
    <time_frame>2 hours post-administration on Days 0 and 28</time_frame>
    <description>From administration of any dose, immediate reaction measured as observed by study staff or reported by the subject to study staff in case of an anaphylactic reaction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events Associated With Intranasal Vaccination</measure>
    <time_frame>Greater than 2 hours through 7 days following any dose</time_frame>
    <description>From solicited local and systemic reactions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All Other Adverse Events</measure>
    <time_frame>7 days following any dose</time_frame>
    <description>Including unsolicited events and abnormal laboratory findings</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Serious Adverse Events (SAEs)</measure>
    <time_frame>Within 4 weeks of receipt of any dose</time_frame>
    <description>Including abnormal laboratory findings</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number/Percentage of Subjects With Seroconversion for Serum Hemagglutination Inhibition (HAI)</measure>
    <time_frame>28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>Seroconversion was defined as at least a four-fold rise after each dose from baseline or as the mean titer after each dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number/Percentage of Subjects With Serum Neutralizing Antibodies</measure>
    <time_frame>28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>Measured using microneutralization assay. Seroconversion was defined as at least a four-fold rise after each dose from baseline or as the mean titer after each dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number/Percentage of Subjects With Seroconversion for Serum Immunoglobulin A (IgA)</measure>
    <time_frame>28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>Measured by enzyme-linked immunoassay (EIA). Seroconversion was defined as at least a four-fold rise after each dose from baseline or as the mean titer after each dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number/Percentage of Subjects With Seroconversion for Serum Immunoglobulin G (IgG)</measure>
    <time_frame>28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>Measured by enzyme-linked immunoassay (EIA). Seroconversion was defined as at least a four-fold rise after each dose from baseline or as the mean titer after each dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number/Percentage of Subjects With Seroconversion for Mucosal IgA</measure>
    <time_frame>28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>From nasal wick specimen. Seroconversion was defined as at least a four-fold rise after each dose from baseline or as the mean titer after each dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) for Serum Hemagglutination Inhibition (HAI) Antibodies (4 Haemagglutinating Units of H7N3)</measure>
    <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>HAI test was performed by standard procedure with human red blood cells utilizing either 4 haemagglutinating units (HAU) of H7N3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) for Serum Hemagglutination Inhibition (HAI) Antibodies (2 Haemagglutinating Units of H7N3)</measure>
    <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>HAI test was performed by standard procedure with human red blood cells utilizing 2 haemagglutinating units (HAU) of H7N3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) for Serum Neutralizing Antibodies</measure>
    <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
    <description>Measured by microneutralization assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number/Percentage of Vaccinated Subjects Shedding Virus After First Dose</measure>
    <time_frame>Days 1, 2, 3 &amp; 4</time_frame>
    <description>Detected by real-time reverse transcriptase polymerase chain reaction (rRTPCR) in nasal swabs or conjunctival swabs or by isolation in chicken embryos.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number/Percentage of Subjects Shedding Virus After Second Dose</measure>
    <time_frame>Day 29, 30, 31 and 32</time_frame>
    <description>Detected by real-time reverse transcriptase polymerase chain reaction (rRTPCR) in nasal swabs or conjunctival swabs or by isolation in chicken embryos.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number/Percentage of Subjects Exhibiting CD4+ IFNγ+ Responses</measure>
    <time_frame>Days 0, 28 &amp; 56</time_frame>
    <description>H7N3-specific T cell responses were examined in peripheral blood mononuclear cells (PBMCs) obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.
Increases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number/Percentage of Subjects Exhibiting CD4+ IFNγ+ Central Memory T Cell Responses</measure>
    <time_frame>Days 0, 28 &amp; 56</time_frame>
    <description>H7N3-specific T cell responses were examined in PBMCs obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.
Increases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number/Percentage of Subjects Exhibiting CD4+ IFNγ+ Effector Memory T Cell Responses</measure>
    <time_frame>Days 0, 28 &amp; 56</time_frame>
    <description>H7N3-specific T cell responses were examined in PBMCs obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.
Increases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number/Percentage of Subjects Exhibiting CD8+ IFNγ+ Responses</measure>
    <time_frame>Days 0, 28 &amp; 56</time_frame>
    <description>H7N3-specific T cell responses were examined in PBMCs obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.
Increases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number/Percentage of Subjects Exhibiting CD8+ IFNγ+ Central Memory T Cell Responses</measure>
    <time_frame>Days 0, 28 &amp; 56</time_frame>
    <description>H7N3-specific T cell responses were examined in PBMCs obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.
Increases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number/Percentage of Subjects Exhibiting CD8+ IFNγ+ Effector Memory T Cell Responses</measure>
    <time_frame>Days 0, 28 &amp; 56</time_frame>
    <description>H7N3-specific T cell responses were examined in PBMCs obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.
Increases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Influenza</condition>
  <condition>Avian Influenza</condition>
  <arm_group>
    <arm_group_label>LAIV H7N3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log egg infectious dose (EID) 50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.
Duration of treatment: Two doses were delivered, one on Day 0 and one on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol
Duration of treatment: Two doses were delivered, one on Day 0 and one on Day 28</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LAIV H7N3</intervention_name>
    <description>2 doses of vaccine</description>
    <arm_group_label>LAIV H7N3</arm_group_label>
    <other_name>A/17/mallard/Netherlands/00/95 (H7N3)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>2 doses of placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Legal male or female adult 18 through 49 years of age at the enrollment visit.

          -  Literate and willing to provide written informed consent.

          -  Free of obvious health problems, as established by the medical history and screening
             evaluations, including physical examination.

          -  Capable and willing to complete diary cards and willing to return for all follow-up
             visits

          -  Willing to comply with the rules of the isolation unit (including willing and able to
             take oseltamivir influenza antiviral medication, should that be recommended by a study
             physician).

          -  For females, willing to take reliable birth control measures throughout the entire
             period of participation in the study.

        Exclusion Criteria:

          -  Participation in another clinical trial involving any therapy within the previous
             three months or planned enrollment in such a trial during the period of this study.

          -  Receipt of any non-study vaccine within four weeks prior to enrollment or refusal to
             postpone receipt of such vaccines until four weeks after study completion.

          -  Practice of nasal irrigation on a regular basis within the past six months or has
             engaged in nasal irrigation within two weeks prior to enrollment.

          -  Recent history of frequent nose bleeds (&gt;5 within the past year).

          -  Clinically relevant abnormal paranasal anatomy.

          -  Recent history (within the past month) of rhino or sinus surgery, or surgery for any
             traumatic injury of the nose.

          -  Current or recent (within two weeks of enrollment) acute respiratory illness with or
             without fever.

          -  Other acute illness at the time of study enrollment.

          -  Receipt of immune globulin or other blood products within three months prior to study
             enrollment or planned receipt of such products during the period of subject
             participation in the study.

          -  Chronic administration (defined as more than 14 consecutively-prescribed days) of
             immunosuppressants or other immune-modulating therapy within six months prior to study
             enrollment. (For corticosteroids, this means prednisone or equivalent, &gt;=0.5 mg per kg
             per day; topical steroids are allowed, exclusive of nasal.)

          -  Participation in any previous trial of any H5 or H7 containing influenza vaccine.

          -  History of asthma.

          -  Hypersensitivity after previous administration of any influenza vaccine.

          -  History of wheezing after past receipt of any live influenza vaccine.

          -  Other AE following immunization, at least possibly related to previous receipt of any
             influenza vaccine.

          -  Suspected or known hypersensitivity to any of the study vaccine components, including
             chicken or egg protein.

          -  Seasonal (autumnal) hypersensitivity to the natural environment.

          -  Acute or chronic clinically significant pulmonary, cardiovascular, hepatic, metabolic,
             neurologic, psychiatric or renal functional abnormality, as determined by medical
             history, physical examination or clinical laboratory screening tests, which in the
             opinion of the investigator, might interfere with the study objectives. Subjects with
             physical examination findings or clinical laboratory screening results which would be
             graded 2 or higher on the AE severity grading scale will be excluded from entry into
             the study and will be excluded from receipt of dose two of study vaccine or placebo.

          -  History of leukemia or any other blood or solid organ cancer.

          -  History of thrombocytopenic purpura or known bleeding disorder.

          -  History of seizures.

          -  Known or suspected immunosuppressive or immunodeficient condition of any kind,
             including HIV infection.

          -  Known chronic HBV or HCV infection.

          -  Known tuberculosis infection or evidence of previous tuberculosis exposure.

          -  History of chronic alcohol abuse and/or illegal drug use.

          -  Claustrophobia or sociophobia.

          -  Pregnancy or lactation. (A negative pregnancy test will be required before
             administration of study vaccine or placebo for all women of childbearing potential.)

          -  Any condition that, in the opinion of the investigator, would increase the health risk
             to the subject if he/she participates in the study or would interfere with the
             evaluation of the study objectives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oleg I Kiselev, MD, PhD, DSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute of Influenza</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Larisa G Rudenko, MD, PhD, DSc</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Experimental Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathleen M Neuzil, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>PATH Vaccine Solutions</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Igor Victorevich</last_name>
    <role>Study Director</role>
    <affiliation>Microgen Scientific Industrial Company for Immunobiological Medicines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute of Influenza</name>
      <address>
        <city>St Petersburg</city>
        <zip>197376</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 5, 2012</study_first_submitted>
  <study_first_submitted_qc>January 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2012</study_first_posted>
  <results_first_submitted>July 16, 2018</results_first_submitted>
  <results_first_submitted_qc>January 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 22, 2019</results_first_posted>
  <last_update_submitted>January 22, 2019</last_update_submitted>
  <last_update_submitted_qc>January 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Pandemic</keyword>
  <keyword>H7N3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LAIV H7N3</title>
          <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log egg infectious dose (EID) 50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.
Duration of treatment: Two doses were delivered, one on Day 0 and one on Day 28.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol
Duration of treatment: Two doses were delivered, one on Day 0 and one on Day 28
placebo: 2 doses of placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Dose 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Dose 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LAIV H7N3</title>
          <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.
Duration of treatment: Two doses were delivered, one on Day 0 and one on Day 28.
LAIV H7N3: 2 doses of vaccine</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol
Duration of treatment: Two doses were delivered, one on Day 0 and one on Day 28
placebo: 2 doses of placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.1" spread="10.3"/>
                    <measurement group_id="B2" value="38.5" spread="9.7"/>
                    <measurement group_id="B3" value="32.2" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Immediate Reactions</title>
        <description>From administration of any dose, immediate reaction measured as observed by study staff or reported by the subject to study staff in case of an anaphylactic reaction.</description>
        <time_frame>2 hours post-administration on Days 0 and 28</time_frame>
        <population>Intent-to-treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>LAIV H7N3: Dose 1 (Day 0)</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Dose 1 (Day 0)</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
          <group group_id="O3">
            <title>LAIV H7N3: Dose 2 (Day 28)</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O4">
            <title>Placebo: Dose 2 (Day 28)</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Immediate Reactions</title>
          <description>From administration of any dose, immediate reaction measured as observed by study staff or reported by the subject to study staff in case of an anaphylactic reaction.</description>
          <population>Intent-to-treat (ITT) population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Immediate reaction</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No immediate reaction</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events Associated With Intranasal Vaccination</title>
        <description>From solicited local and systemic reactions</description>
        <time_frame>Greater than 2 hours through 7 days following any dose</time_frame>
        <population>Intent‐To‐Treat (ITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>LAIV H7N3: Dose 1</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Dose 1</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
          <group group_id="O3">
            <title>LAIV H7N3: Dose 2</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O4">
            <title>Placebo: Dose 2</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events Associated With Intranasal Vaccination</title>
          <description>From solicited local and systemic reactions</description>
          <population>Intent‐To‐Treat (ITT) Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Any local or systemic reaction</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No local or systemic reaction</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>All Other Adverse Events</title>
        <description>Including unsolicited events and abnormal laboratory findings</description>
        <time_frame>7 days following any dose</time_frame>
        <population>Total events among Intent‐To‐Treat (ITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>LAIV H7N3: Dose 1</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Dose 1</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
          <group group_id="O3">
            <title>LAIV H7N3: Dose 2</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O4">
            <title>Placebo: Dose 2</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
        </group_list>
        <measure>
          <title>All Other Adverse Events</title>
          <description>Including unsolicited events and abnormal laboratory findings</description>
          <population>Total events among Intent‐To‐Treat (ITT) Population</population>
          <units>adverse events</units>
          <param>Count of Units</param>
          <units_analyzed>adverse events</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>adverse events</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unrelated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="84"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Serious Adverse Events (SAEs)</title>
        <description>Including abnormal laboratory findings</description>
        <time_frame>Within 4 weeks of receipt of any dose</time_frame>
        <population>Intent‐To‐Treat (ITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>LAIV H7N3: Dose 1</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Dose 1</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
          <group group_id="O3">
            <title>LAIV H7N3: Dose 2</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O4">
            <title>Placebo: Dose 2</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Serious Adverse Events (SAEs)</title>
          <description>Including abnormal laboratory findings</description>
          <population>Intent‐To‐Treat (ITT) Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Any serious adverse event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No serious adverse event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number/Percentage of Subjects With Seroconversion for Serum Hemagglutination Inhibition (HAI)</title>
        <description>Seroconversion was defined as at least a four-fold rise after each dose from baseline or as the mean titer after each dose</description>
        <time_frame>28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>Per-Protocol (PP) Population</population>
        <group_list>
          <group group_id="O1">
            <title>LAIV H7N3: Dose 1</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Dose 1</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
          <group group_id="O3">
            <title>LAIV H7N3: Dose 2</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O4">
            <title>Placebo: Dose 2</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percentage of Subjects With Seroconversion for Serum Hemagglutination Inhibition (HAI)</title>
          <description>Seroconversion was defined as at least a four-fold rise after each dose from baseline or as the mean titer after each dose</description>
          <population>Per-Protocol (PP) Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Seroconversion</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No seroconversion</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number/Percentage of Subjects With Serum Neutralizing Antibodies</title>
        <description>Measured using microneutralization assay. Seroconversion was defined as at least a four-fold rise after each dose from baseline or as the mean titer after each dose</description>
        <time_frame>28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>Per-Protocol (PP) Population</population>
        <group_list>
          <group group_id="O1">
            <title>LAIV H7N3: Dose 1</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Dose 1</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
          <group group_id="O3">
            <title>LAIV H7N3: Dose 2</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O4">
            <title>Placebo: Dose 2</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percentage of Subjects With Serum Neutralizing Antibodies</title>
          <description>Measured using microneutralization assay. Seroconversion was defined as at least a four-fold rise after each dose from baseline or as the mean titer after each dose</description>
          <population>Per-Protocol (PP) Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Seroconversion</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No seroconversion</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number/Percentage of Subjects With Seroconversion for Serum Immunoglobulin A (IgA)</title>
        <description>Measured by enzyme-linked immunoassay (EIA). Seroconversion was defined as at least a four-fold rise after each dose from baseline or as the mean titer after each dose</description>
        <time_frame>28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>Per-Protocol (PP) Population</population>
        <group_list>
          <group group_id="O1">
            <title>LAIV H7N3: Dose 1</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Dose 1</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
          <group group_id="O3">
            <title>LAIV H7N3: Dose 2</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O4">
            <title>Placebo: Dose 2</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percentage of Subjects With Seroconversion for Serum Immunoglobulin A (IgA)</title>
          <description>Measured by enzyme-linked immunoassay (EIA). Seroconversion was defined as at least a four-fold rise after each dose from baseline or as the mean titer after each dose</description>
          <population>Per-Protocol (PP) Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Seroconversion</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No seroconversion</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number/Percentage of Subjects With Seroconversion for Serum Immunoglobulin G (IgG)</title>
        <description>Measured by enzyme-linked immunoassay (EIA). Seroconversion was defined as at least a four-fold rise after each dose from baseline or as the mean titer after each dose</description>
        <time_frame>28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>Per-Protocol (PP) Population</population>
        <group_list>
          <group group_id="O1">
            <title>LAIV H7N3: Dose 1</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Dose 1</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
          <group group_id="O3">
            <title>LAIV H7N3: Dose 2</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O4">
            <title>Placebo: Dose 2</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percentage of Subjects With Seroconversion for Serum Immunoglobulin G (IgG)</title>
          <description>Measured by enzyme-linked immunoassay (EIA). Seroconversion was defined as at least a four-fold rise after each dose from baseline or as the mean titer after each dose</description>
          <population>Per-Protocol (PP) Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Seroconversion</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No seroconversion</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number/Percentage of Subjects With Seroconversion for Mucosal IgA</title>
        <description>From nasal wick specimen. Seroconversion was defined as at least a four-fold rise after each dose from baseline or as the mean titer after each dose</description>
        <time_frame>28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>Per-Protocol (PP) Population</population>
        <group_list>
          <group group_id="O1">
            <title>LAIV H7N3: Dose 1</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Dose 1</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
          <group group_id="O3">
            <title>LAIV H7N3: Dose 2</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O4">
            <title>Placebo: Dose 2</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percentage of Subjects With Seroconversion for Mucosal IgA</title>
          <description>From nasal wick specimen. Seroconversion was defined as at least a four-fold rise after each dose from baseline or as the mean titer after each dose</description>
          <population>Per-Protocol (PP) Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Seroconversion</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No seroconversion</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) for Serum Hemagglutination Inhibition (HAI) Antibodies (4 Haemagglutinating Units of H7N3)</title>
        <description>HAI test was performed by standard procedure with human red blood cells utilizing either 4 haemagglutinating units (HAU) of H7N3.</description>
        <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>Per-Protocol (PP) Population</population>
        <group_list>
          <group group_id="O1">
            <title>LAIV H7N3</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.
Duration of treatment: Two doses were delivered, one on Day 0 and one on Day 28.
LAIV H7N3: 2 doses of vaccine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol
Duration of treatment: Two doses were delivered, one on Day 0 and one on Day 28
placebo: 2 doses of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) for Serum Hemagglutination Inhibition (HAI) Antibodies (4 Haemagglutinating Units of H7N3)</title>
          <description>HAI test was performed by standard procedure with human red blood cells utilizing either 4 haemagglutinating units (HAU) of H7N3.</description>
          <population>Per-Protocol (PP) Population</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="2.5" upper_limit="3.1"/>
                    <measurement group_id="O2" value="3.3" lower_limit="2.3" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="2.8" upper_limit="4.4"/>
                    <measurement group_id="O2" value="3.3" lower_limit="2.3" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="3.5" upper_limit="6.1"/>
                    <measurement group_id="O2" value="3.5" lower_limit="2.5" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) for Serum Hemagglutination Inhibition (HAI) Antibodies (2 Haemagglutinating Units of H7N3)</title>
        <description>HAI test was performed by standard procedure with human red blood cells utilizing 2 haemagglutinating units (HAU) of H7N3.</description>
        <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>Per-Protocol (PP) population</population>
        <group_list>
          <group group_id="O1">
            <title>LAIV H7N3</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.
Duration of treatment: Two doses were delivered, one on Day 0 and one on Day 28.
LAIV H7N3: 2 doses of vaccine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol
Duration of treatment: Two doses were delivered, one on Day 0 and one on Day 28
placebo: 2 doses of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) for Serum Hemagglutination Inhibition (HAI) Antibodies (2 Haemagglutinating Units of H7N3)</title>
          <description>HAI test was performed by standard procedure with human red blood cells utilizing 2 haemagglutinating units (HAU) of H7N3.</description>
          <population>Per-Protocol (PP) population</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2.6" upper_limit="3.5"/>
                    <measurement group_id="O2" value="4.1" lower_limit="2.7" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="4.2" upper_limit="7.2"/>
                    <measurement group_id="O2" value="4.1" lower_limit="2.7" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="5.2" upper_limit="9.4"/>
                    <measurement group_id="O2" value="4.7" lower_limit="2.8" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) for Serum Neutralizing Antibodies</title>
        <description>Measured by microneutralization assay</description>
        <time_frame>0 days, 28 days (Dose 1) and 56 days (Dose 2)</time_frame>
        <population>Per-Protocol (PP) population</population>
        <group_list>
          <group group_id="O1">
            <title>LAIV H7N3</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.
Duration of treatment: Two doses were delivered, one on Day 0 and one on Day 28.
LAIV H7N3: 2 doses of vaccine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol
Duration of treatment: Two doses were delivered, one on Day 0 and one on Day 28
placebo: 2 doses of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) for Serum Neutralizing Antibodies</title>
          <description>Measured by microneutralization assay</description>
          <population>Per-Protocol (PP) population</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="3.5" upper_limit="5.1"/>
                    <measurement group_id="O2" value="4.4" lower_limit="2.8" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" lower_limit="4.5" upper_limit="8.5"/>
                    <measurement group_id="O2" value="4.4" lower_limit="2.8" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" lower_limit="8.2" upper_limit="18.7"/>
                    <measurement group_id="O2" value="5.0" lower_limit="3.1" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number/Percentage of Vaccinated Subjects Shedding Virus After First Dose</title>
        <description>Detected by real-time reverse transcriptase polymerase chain reaction (rRTPCR) in nasal swabs or conjunctival swabs or by isolation in chicken embryos.</description>
        <time_frame>Days 1, 2, 3 &amp; 4</time_frame>
        <population>Intent-To-Treat (ITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Day 1</title>
            <description>LAIV H7N3 Arm</description>
          </group>
          <group group_id="O2">
            <title>Day 2</title>
            <description>LAIV H7N3 Arm</description>
          </group>
          <group group_id="O3">
            <title>Day 3</title>
            <description>LAIV H7N3 Arm</description>
          </group>
          <group group_id="O4">
            <title>Day 4</title>
            <description>LAIV H7N3 Arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percentage of Vaccinated Subjects Shedding Virus After First Dose</title>
          <description>Detected by real-time reverse transcriptase polymerase chain reaction (rRTPCR) in nasal swabs or conjunctival swabs or by isolation in chicken embryos.</description>
          <population>Intent-To-Treat (ITT) Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Shedding</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No shedding</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number/Percentage of Subjects Shedding Virus After Second Dose</title>
        <description>Detected by real-time reverse transcriptase polymerase chain reaction (rRTPCR) in nasal swabs or conjunctival swabs or by isolation in chicken embryos.</description>
        <time_frame>Day 29, 30, 31 and 32</time_frame>
        <population>Per‐Protocol (PP) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Day 29</title>
            <description>LAIV H7N3 Arm</description>
          </group>
          <group group_id="O2">
            <title>Day 30</title>
            <description>LAIV H7N3 Arm</description>
          </group>
          <group group_id="O3">
            <title>Day 31</title>
            <description>LAIV H7N3 Arm</description>
          </group>
          <group group_id="O4">
            <title>Day 32</title>
            <description>LAIV H7N3 Arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percentage of Subjects Shedding Virus After Second Dose</title>
          <description>Detected by real-time reverse transcriptase polymerase chain reaction (rRTPCR) in nasal swabs or conjunctival swabs or by isolation in chicken embryos.</description>
          <population>Per‐Protocol (PP) Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Shedding</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No shedding</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number/Percentage of Subjects Exhibiting CD4+ IFNγ+ Responses</title>
        <description>H7N3-specific T cell responses were examined in peripheral blood mononuclear cells (PBMCs) obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.
Increases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.</description>
        <time_frame>Days 0, 28 &amp; 56</time_frame>
        <population>Per-Protocol (PP) population that received 2 doses of either vaccine or placebo</population>
        <group_list>
          <group group_id="O1">
            <title>LAIV H7N3: Day 0 (After Dose 1)</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Day 0 (After Dose 1)</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
          <group group_id="O3">
            <title>LAIV H7N3: Day 28 (Dose 2)</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O4">
            <title>Placebo: Day 28 (Dose 2)</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
          <group group_id="O5">
            <title>LAIV H7N3: Day 56 (28 Days Past Dose 2)</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O6">
            <title>Placebo: Day 56 (28 Days Past Dose 2)</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percentage of Subjects Exhibiting CD4+ IFNγ+ Responses</title>
          <description>H7N3-specific T cell responses were examined in peripheral blood mononuclear cells (PBMCs) obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.
Increases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.</description>
          <population>Per-Protocol (PP) population that received 2 doses of either vaccine or placebo</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Positive response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number/Percentage of Subjects Exhibiting CD4+ IFNγ+ Central Memory T Cell Responses</title>
        <description>H7N3-specific T cell responses were examined in PBMCs obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.
Increases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.</description>
        <time_frame>Days 0, 28 &amp; 56</time_frame>
        <population>Per-Protocol (PP) population that received 2 doses of either vaccine or placebo</population>
        <group_list>
          <group group_id="O1">
            <title>LAIV H7N3: Day 0 (After Dose 1)</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Day 0 (After Dose 1)</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
          <group group_id="O3">
            <title>LAIV H7N3: Day 28 (Dose 2)</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O4">
            <title>Placebo: Day 28 (Dose 2)</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
          <group group_id="O5">
            <title>LAIV H7N3: Day 56 (28 Days Past Dose 2)</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O6">
            <title>Placebo: Day 56 (28 Days Past Dose 2)</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percentage of Subjects Exhibiting CD4+ IFNγ+ Central Memory T Cell Responses</title>
          <description>H7N3-specific T cell responses were examined in PBMCs obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.
Increases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.</description>
          <population>Per-Protocol (PP) population that received 2 doses of either vaccine or placebo</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Positive response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number/Percentage of Subjects Exhibiting CD4+ IFNγ+ Effector Memory T Cell Responses</title>
        <description>H7N3-specific T cell responses were examined in PBMCs obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.
Increases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.</description>
        <time_frame>Days 0, 28 &amp; 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LAIV H7N3: Dose 1 (Day 0)</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Dose 1 (Day 0)</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
          <group group_id="O3">
            <title>LAIV H7N3: Day 28 (Dose 2)</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O4">
            <title>Placebo: Day 28 (Dose 2)</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
          <group group_id="O5">
            <title>LAIV H7N3: Day 56 (28 Days Past Dose 2)</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O6">
            <title>Placebo: Day 56 (28 Days Past Dose 2)</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percentage of Subjects Exhibiting CD4+ IFNγ+ Effector Memory T Cell Responses</title>
          <description>H7N3-specific T cell responses were examined in PBMCs obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.
Increases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Positive response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="26"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number/Percentage of Subjects Exhibiting CD8+ IFNγ+ Responses</title>
        <description>H7N3-specific T cell responses were examined in PBMCs obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.
Increases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.</description>
        <time_frame>Days 0, 28 &amp; 56</time_frame>
        <population>Per-Protocol (PP) population that received 2 doses of either vaccine or placebo</population>
        <group_list>
          <group group_id="O1">
            <title>LAIV H7N3: Dose 1 (Day 0)</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Dose 1 (Day 0)</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
          <group group_id="O3">
            <title>LAIV H7N3: Day 28 (Dose 2)</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O4">
            <title>Placebo: Day 28 (Dose 2)</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
          <group group_id="O5">
            <title>LAIV H7N3: Day 56 (28 Days Past Dose 2)</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O6">
            <title>Placebo: Day 56 (28 Days Past Dose 2)</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percentage of Subjects Exhibiting CD8+ IFNγ+ Responses</title>
          <description>H7N3-specific T cell responses were examined in PBMCs obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.
Increases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.</description>
          <population>Per-Protocol (PP) population that received 2 doses of either vaccine or placebo</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Positive response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number/Percentage of Subjects Exhibiting CD8+ IFNγ+ Central Memory T Cell Responses</title>
        <description>H7N3-specific T cell responses were examined in PBMCs obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.
Increases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.</description>
        <time_frame>Days 0, 28 &amp; 56</time_frame>
        <population>Per-Protocol (PP) population that received 2 doses of either vaccine or placebo</population>
        <group_list>
          <group group_id="O1">
            <title>LAIV H7N3: Dose 1 (Day 0)</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Dose 1 (Day 0)</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
          <group group_id="O3">
            <title>LAIV H7N3: Day 28 (Dose 2)</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O4">
            <title>Placebo: Day 28 (Dose 2)</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
          <group group_id="O5">
            <title>LAIV H7N3: Day 56 (28 Days Past Dose 2)</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O6">
            <title>Placebo: Day 56 (28 Days Past Dose 2)</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percentage of Subjects Exhibiting CD8+ IFNγ+ Central Memory T Cell Responses</title>
          <description>H7N3-specific T cell responses were examined in PBMCs obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.
Increases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.</description>
          <population>Per-Protocol (PP) population that received 2 doses of either vaccine or placebo</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Positive response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="23"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number/Percentage of Subjects Exhibiting CD8+ IFNγ+ Effector Memory T Cell Responses</title>
        <description>H7N3-specific T cell responses were examined in PBMCs obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.
Increases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.</description>
        <time_frame>Days 0, 28 &amp; 56</time_frame>
        <population>Per-Protocol (PP) population that received 2 doses of either vaccine or placebo</population>
        <group_list>
          <group group_id="O1">
            <title>LAIV H7N3: Dose 1 (Day 0)</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Dose 1 (Day 0)</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
          <group group_id="O3">
            <title>LAIV H7N3: Day 28 (Dose 2)</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O4">
            <title>Placebo: Day 28 (Dose 2)</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
          <group group_id="O5">
            <title>LAIV H7N3: Day 56 (28 Days Past Dose 2)</title>
            <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
          </group>
          <group group_id="O6">
            <title>Placebo: Day 56 (28 Days Past Dose 2)</title>
            <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percentage of Subjects Exhibiting CD8+ IFNγ+ Effector Memory T Cell Responses</title>
          <description>H7N3-specific T cell responses were examined in PBMCs obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.
Increases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.</description>
          <population>Per-Protocol (PP) population that received 2 doses of either vaccine or placebo</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Positive response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 56 days following dosing</time_frame>
      <desc>For the assessment of safety, subjects were assessed for adverse reactions twice daily (early morning and late afternoon) for 7 days.
An ear, nose, and throat (ENT) examination was performed on Days 7, 28, 35, and 56.
Blood and urine specimens were also collected on Days 7, 28 (prior to administration of the second dose of study vaccine or placebo), 35 and 56, for testing by routine biochemical and hematological blood tests and by urinalysis by dipstick.</desc>
      <group_list>
        <group group_id="E1">
          <title>LAIV H7N3: Dose 1</title>
          <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
        </group>
        <group group_id="E2">
          <title>Placebo: Dose 1</title>
          <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
        </group>
        <group group_id="E3">
          <title>LAIV H7N3: Dose 2</title>
          <description>Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
Dose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.
Route of administration: Intranasal aerosol.</description>
        </group>
        <group group_id="E4">
          <title>Placebo: Dose 2</title>
          <description>Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
Dose: 0.5 ml; 0.25 ml/nare
Route of administration: Intranasal aerosol</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphocytosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Monocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood alkaline phosphatase decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blood calcium increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blood chloride increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Mean cell hemoglobin concentration increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Monocyte count increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total protein decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Red blood cell increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Red blood cell sedimentation rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urine leukocyte esterase positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was completed as expected.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jorge Flores</name_or_title>
      <organization>PATH</organization>
      <phone>(202) 822-0033</phone>
      <email>jeflores@path.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

